Botanix Pharmaceuticals (BOT) H2 2024 earnings summary

Executive summary

• FDA approved Sofdra (sofpironium) topical gel for primary axillary hyperhidrosis in June 2024, marking a major milestone for the company.

• Significant progress made in commercial launch preparations for Sofdra in the US, with early patient access planned for late Q3 CY2024 and broader launch in Q4 CY2024.

• Three capital raisings during the year totaling A$96 million, strengthening the balance sheet for launch activities and working capital.

• Net working capital surplus of $79.2 million and cash balance of $79.3 million at 30 June 2024, providing a strong financial position.

Financial highlights

• Comprehensive loss after tax for FY2024 was $13.7 million, compared to $8.9 million in FY2023, mainly due to regulatory and launch costs for Sofdra.

• Revenue from continuing operations increased to $601,820 from $102,934 year-over-year, primarily from royalties.

• Net cash outflows from operating activities were $8.1 million, an improvement from $12.1 million in the prior year.

• Research and development incentive income decreased to $1.47 million from $3.67 million year-over-year.

• No dividends were paid or declared for the year.

Outlook and guidance

• Confident in sufficient funds to meet working capital needs and ability to raise additional capital if required.

• Focused on successful US launch of Sofdra, with commercial, payer, and telemedicine strategies in place.

• Ongoing engagement with US payers, supply chain, and marketing to optimize launch.